

1 Mapping the aetiological foundations of the heart failure 2 spectrum using human genetics

3 Word count: 3889 (excluding methods)

4 5 Supplementary files

- 6 • **Supplementary Figures 1-20**
- 7 • **Supplementary Tables 1-23**
- 8 • **Supplementary Note**
- 9 • **Supplementary Materials** (QC summary and locus characterisation)

10 Authors

11 Albert Henry^{1,2}, Xiaodong Mo³, Chris Finan¹, Mark D. Chaffin⁴, Doug Speed⁵, Hanane Issa², Spiros
12 Denaxas^{6,2,7,8}, James S. Ware^{9,10,11,12,4}, Sean L. Zheng^{9,11}, Anders Malarstig^{13,14}, Jasmine Gratton¹,
13 Isabelle Bond¹, Carolina Roselli^{15,4}, David Miller¹⁶, Sandesh Chopade¹, A. Floriaan Schmidt^{1,17,18}, Erik
14 Abner¹⁹, Lance Adams²⁰, Charlotte Andersson^{21,22}, Krishna G. Aragam^{23,24,4}, Johan Ärnlöv^{25,26},
15 Geraldine Asselin²⁷, Anna Axelsson Raja²⁸, Joshua D. Backman²⁹, Traci M. Bartz³⁰, Kiran J.
16 Biddinger^{23,4}, Mary L. Biggs^{30,31}, Heather L. Bloom³², Eric Boersma³³, Jeffrey Brandimarto³⁴, Michael
17 R. Brown³⁵, Søren Brunak³⁶, Mie Topholm Bruun³⁷, Leonard Buckbinder¹⁴, Henning Bundgaard²⁸,
18 David J. Carey³⁸, Daniel I. Chasman^{39,40}, Xing Chen¹⁴, James P. Cook⁴¹, Tomasz Czuba⁴², Simon de
19 Denus^{27,43}, Abbas Dehghan⁴⁴, Graciela E. Delgado⁴⁵, Alexander S. Doney⁴⁶, Marcus Dörr^{47,48}, Joseph
20 Dowsett⁴⁹, Samuel C. Dudley⁵⁰, Gunnar Engström⁵¹, Christian Erikstrup^{52,53}, Tõnu Esko^{19,4}, Eric H.
21 Farber-Eger⁵⁴, Stephan B. Felix^{47,48}, Sarah Finer⁵⁵, Ian Ford⁵⁶, Mohsen Ghanbari⁵⁷, Sahar
22 Ghasemi^{58,48,59}, Jonas Ghouse⁶⁰, Vilmantas Giedraitis⁶¹, Franco Giulianini³⁹, John S. Gottdiener⁶²,
23 Stefan Gross^{47,48}, Daniél F. Guðbjartsson^{63,64}, Hongsheng Gui⁶⁵, Rebecca Gutmann⁶⁶, Sara Hägg⁶⁷,
24 Christopher M. Haggerty³⁸, Åsa K. Hedman¹³, Anna Helgadottir⁶³, Harry Hemingway^{2,6}, Hans
25 Hillege¹⁵, Craig L. Hyde¹⁴, Bitten Aagaard Jensen⁶⁸, J. Wouter Jukema^{69,70}, Isabella Kardys³³, Ravi
26 Karra^{71,72}, Maryam Kavousi⁵⁷, Jorge R. Kizer⁷³, Marcus E. Kleber⁴⁵, Lars Køber⁷⁴, Andrea
27 Koekemoer⁷⁵, Karoline Kuchenbaecker^{76,77}, Yi-Pin Lai¹⁴, David Lanfear^{65,78}, Claudia
28 Langenberg^{79,80,81}, Honghuang Lin^{22,82}, Lars Lind⁸³, Cecilia M. Lindgren^{84,4,85}, Peter P. Liu^{86,87,88}, Barry
29 London⁸⁹, Brandon D. Lowery⁵⁴, Jian'an Luan⁸¹, Steven A. Lubitz^{90,4}, Patrik Magnusson⁶⁷, Kenneth B.
30 Margulies³⁴, Nicholas A. Marston⁹¹, Hilary Martin⁹², Winfried März^{93,94,45}, Olle Melander⁹⁵, Ify R.
31 Mordi⁴⁶, Michael P. Morley³⁴, Andrew P. Morris^{41,85}, Alanna C. Morrison³⁵, Lori Morton⁹⁶, Michael W.
32 Nagle¹⁴, Christopher P. Nelson⁷⁵, Alexander Niessner⁹⁷, Teemu Niiranen^{98,99}, Raymond Noordam¹⁰⁰,
33 Christoph Nowak²⁵, Michelle L. O'Donoghue⁹¹, Sisse Rye Ostrowski^{49,101}, Anjali T. Owens³⁴, Colin N.
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 A. Palmer¹⁰², Guillaume Paré^{103,104,105}, Ole Birger Pedersen^{106,101}, Markus Perola⁹⁹, Marie
35 Pigeyre^{107,105}, Bruce M. Psaty^{108,109}, Kenneth M. Rice³⁰, Paul M. Ridker^{39,40}, Simon P. R. Romaine⁷⁵,
36 Jerome I. Rotter^{110,111,112}, Christian T. Ruff⁹¹, Mark S. Sabatine⁹¹, Neneh Sallah², Veikko Salomaa⁹⁹,
37 Naveed Sattar¹¹³, Alaa A. Shalaby¹¹⁴, Akshay Shekhar⁹⁶, Diane T. Smelser³⁸, Nicholas L.
38 Smith^{115,109,116}, Erik Sørensen¹¹⁷, Sundararajan Srinivasan¹⁰², Kari Stefansson^{63,118}, Garðar
39 Sveinbjörnsson⁶³, Per Svensson^{119,120}, Mari-Liis Tammesoo¹⁹, Jean-Claude Tardif^{27,121}, Maris Teder-
40 Laving¹⁹, Alexander Teumer^{48,122,59}, Guðmundur Thorgeirsson^{63,123,118}, Unnur Thorsteinsdottir^{63,118},
41 Christian Torp-Pedersen¹²⁴, Vinicius Tragante⁶³, Stella Trompet^{69,100}, Andre G. Uitterlinden^{57,125},
42 Henrik Ullum¹²⁶, Pim van der Harst^{17,15}, David van Heel¹²⁷, Jessica van Setten¹⁷, Marion van Vugt¹⁷,
43 Abirami Veluchamy^{46,102}, Monique Verschuuren^{128,129}, Niek Verweij¹⁵, Christoffer Rasmus Vissing²⁸,
44 Uwe Völker^{48,130}, Adriaan A. Voors¹⁵, Lars Wallentin¹³¹, Yunzhang Wang⁶⁷, Peter E. Weeke⁶⁰, Kerri L.
45 Wiggins³¹, L. Keoki Williams⁶⁵, Yifan Yang³⁴, Bing Yu³⁵, Faiez Zannad¹³², Chaoqun Zheng²⁸, Genes &
46 Health Research Team, DBDS Genomic Consortium, Folkert W. Asselbergs^{2,8,18}, Thomas P.
47 Cappola³⁴, Marie-Pierre Dubé^{27,121}, Michael E. Dunn⁹⁶, Chim C. Lang⁴⁶, Nilesh J. Samani⁷⁵, Svati
48 Shah^{71,133,134}, Ramachandran S. Vasan^{22,135,141}, J. Gustav Smith^{136,42,137,141}, Hilma Holm^{63,141}, Sonia
49 Shah^{3,141}, Patrick T. Ellinor^{90,4,138,139,141}, Aroon D. Hingorani^{1,141}, Quinn Wells^{140,141}, R. Thomas
50 Lumbers^{8,6,2,141}, HERMES Consortium

51

52 **Corresponding author:** R. Thomas Lumbers (t.lumbers@ucl.ac.uk)

53

54 Affiliations

- 55 1. Institute of Cardiovascular Science, University College London, London, England, UK
- 56 2. Institute of Health Informatics, University College London, London, England, UK
- 57 3. Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia
- 58 4. Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard,
59 Cambridge, MA, USA
- 60 5. Center for Quantitative Genetics and Genomics, Aarhus University, Aarhus, Denmark
- 61 6. Health Data Research UK, London, England, UK
- 62 7. British Heart Foundation Data Science Centre, London, England, UK
- 63 8. The National Institute for Health Research University College London Hospitals Biomedical
64 Research Centre, University College London, London, England, UK
- 65 9. National Heart & Lung Institute, Imperial College London, London, England, UK
- 66 10. MRC London Institute of Medical Sciences, Imperial College London, London, England, UK
- 67 11. Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London,
68 England, UK
- 69 12. Hammersmith Hospital, Imperial College Hospitals NHS Trust, London, England, UK
- 70 13. Cardiovascular Medicine unit, Department of Medicine Solna, Karolinska Institute, Stockholm,
71 Sweden
- 72 14. Pfizer Worldwide Research & Development, 1 Portland St, Cambridge, MA, USA
- 73 15. Department of Cardiology, University Medical Center Groningen, University of Groningen,
74 Groningen, The Netherlands

- 75 16. Division of Biosciences, University College London, London
- 76 17. Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht,
77 Utrecht 3584 CX, The Netherlands
- 78 18. Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical
79 Centers, Amsterdam, The Netherlands
- 80 19. Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu 51010, Estonia
- 81 20. Geisinger Health System, Danville, PA, USA
- 82 21. Department of Cardiology, Herlev Gentofte Hospital, Herlev Ringvej 57, Herlev 2650, Denmark
- 83 22. National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study,
84 Framingham, Massachusetts, USA,
- 85 23. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
- 86 24. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- 87 25. Department of Neurobiology, Care Sciences and Society/ Section of Family Medicine and
88 Primary Care, Karolinska Institutet, Stockholm, Sweden
- 89 26. School of Health and Social Sciences, Dalarna University, Falun, Sweden
- 90 27. Montreal Heart Institute, Montreal Heart Institute, Montreal, Canada
- 91 28. Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet,
92 Ingen Lehmanns vej 7, Copenhagen 2100, Denmark
- 93 29. Analytical Genetics, Regeneron Genetics Center, Tarrytown, NY, USA
- 94 30. Department of Biostatistics, University of Washington, Seattle, WA, USA
- 95 31. Department of Medicine, University of Washington, Seattle, WA, USA
- 96 32. Department of Medicine, Division of Cardiology, Emory University Medical Center, Atlanta, GA,
97 USA
- 98 33. Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- 99 34. Penn Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania,
100 Philadelphia, PA, USA
- 101 35. Department of Epidemiology, Human Genetics, and Environmental Sciences, The University of
102 Texas School of Public Health, Houston, TX 77030, USA
- 103 36. Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences,
104 University of Copenhagen, Copenhagen, Denmark
- 105 37. Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
- 106 38. Department of Molecular and Functional Genomics, Geisinger, Danville, PA, USA
- 107 39. Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA
- 108 40. Harvard Medical School, Boston, MA, USA
- 109 41. Department of Biostatistics, University of Liverpool, Liverpool, England, UK
- 110 42. Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and
111 Sahlgrenska University Hospital, Gothenburg, Sweden
- 112 43. Faculty of Pharmacy, Université de Montréal, Montreal, Canada
- 113 44. MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics,
114 Imperial College London, London, England, UK
- 115 45. Vth Department of Medicine (Nephrology, Hypertensiology, Endocrinology, Diabetology,
116 Rheumatology), Medical Faculty of Mannheim, University of Heidelberg, Heidelberg, Germany
- 117 46. Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical
118 School, Dundee DD1 9SY, Scotland, UK
- 119 47. Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany
- 120 48. DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald,
121 Germany
- 122 49. Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet,
123 Copenhagen, Denmark

- 124 50. Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, MN,
125 USA
- 126 51. Department of Clinical Sciences, Lund University, Malmö, Sweden
- 127 52. Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
- 128 53. Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark
- 129 54. Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center,
130 Nashville, TN, USA
- 131 55. Centre for Primary Care and Public Health, Wolfson Institute of Population Health, Queen Mary
132 University of London, London E1 4NS, England, UK
- 133 56. Robertson Center for Biostatistics, Institute of Health and Wellbeing, University of Glasgow,
134 Glasgow, Scotland, UK
- 135 57. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- 136 58. Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of
137 Freiburg, Freiburg, Germany
- 138 59. Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald,
139 Germany
- 140 60. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, , Denmark
- 141 61. Department of Public Health and Caring Sciences, Geriatrics, Uppsala, Sweden
- 142 62. Department of Medicine, Division of Cardiology, University of Maryland School of Medicine,
143 Baltimore, MD, USA
- 144 63. deCODE genetics/Amgen Inc., Sturlugata 8, Reykjavik 101, Iceland
- 145 64. School of Engineering and Natural Sciences, University of Iceland, Sæmundargata 2, Reykjavik
146 101, Iceland
- 147 65. Center for Individualized and Genomic Medicine Research, Department of Internal Medicine,
148 Henry Ford Hospital, Detroit, MI, USA
- 149 66. Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City,
150 IA, USA
- 151 67. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 152 68. Department of Clinical Immunology, Aalborg Univeristy Hospital, Aalborg
- 153 69. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
- 154 70. Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
- 155 71. Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC
156 27710, USA
- 157 72. Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
- 158 73. Cardiology Section, San Francisco Veterans Affairs Health System, and Departments of
159 Medicine, Epidemiology and Biostatistics, University of California San Francisco, CA, USA
- 160 74. Department of Cardiology, Nordsjaellands Hospital, Hilleroed, Copenhagen, Denmark
- 161 75. Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical
162 Research Centre, Glenfield Hospital, Leicester, England, UK
- 163 76. Division of Psychiatry, University College London, London W1T 7NF, England, UK
- 164 77. UCL Genetics Institute, University College London, London WC1E 6BT, England, UK
- 165 78. Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA
- 166 79. Precision Healthcare University Research Institute, Queen Mary University of London, London,
167 England, UK
- 168 80. Computational Medicine, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin,
169 Berlin, Germany
- 170 81. MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge
171 CB2 0QQ, England, UK
- 172 82. Department of Medicine, University of Massachusetts Chan Medical School, Worcester,
173 Massachusetts, USA,

- 174 83. Department of Medical Sciences, Uppsala University, Uppsala, Sweden
175 84. Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of
176 Oxford, Oxford, England, UK
177 85. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, England, UK
178 86. University of Ottawa Heart Institute, Ottawa, ON, Canada
179 87. Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada
180 88. Department of Medicine, University of Ottawa, Ottawa, ON, Canada
181 89. Division of Cardiovascular Medicine and Abboud Cardiovascular Research Center, University of
182 Iowa, Iowa City, IA, USA
183 90. Cardiac Arrhythmia Service and Cardiovascular Research Center, Massachusetts General
184 Hospital, Boston, MA, USA
185 91. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital,
186 Harvard Medical School, Cambridge, MA, USA
187 92. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, England, UK
188 93. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz,
189 Graz, Austria
190 94. Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim, Germany
191 95. Department of Internal Medicine, Clinical Sciences, Lund University and Skåne University
192 Hospital, Malmö, Sweden
193 96. Cardiovascular Research, Regeneron Pharmaceuticals, Tarrytown, NY, USA
194 97. Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna,
195 Austria
196 98. Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland
197 99. National Institute for Health and Welfare, Helsinki, Finland
198 100. Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University
199 Medical Center, Leiden, The Netherlands
200 101. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of
201 Copenhagen, Copenhagen, Denmark
202 102. Division of Population Health and Genomics, University of Dundee, Ninewells Hospital and
203 Medical School, Dundee DD1 9SY, Scotland, UK
204 103. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
205 104. Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
206 105. Population Health Research Institute, Hamilton, ON, Canada
207 106. Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
208 107. Department of Medicine, McMaster University, Hamilton, ON, Canada
209 108. Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA
210 109. Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington,
211 Seattle, WA, USA
212 110. The Institute for Translational Genomics and Population Sciences, Harbor-UCLA Medical
213 Center, Torrance, CA, USA
214 111. Departments of Pediatrics and Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA
215 112. Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, USA
216 113. BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
217 114. Department of Medicine, Division of Cardiology, University of Pittsburgh Medical Center and VA
218 Pittsburgh HCS, Pittsburgh, PA, USA
219 115. Department of Epidemiology, University of Washington, Seattle, WA, USA
220 116. Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office
221 of Research & Development, Seattle, WA, USA
222 117. Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet,
223 Blegdamsvej 9, Copenhagen, Denmark

- 224 118. Department of Medicine, University of Iceland, Sæmundargata 2, Reykjavik 101, Iceland
225 119. Department of Cardiology, Söderjukhuset, Stockholm, Sweden
226 120. Department of Clinical Science and Education-Södersjukhuset, Karolinska Institutet, Stockholm,
227 Sweden
228 121. Faculty of Medicine, Université de Montréal, Montreal, Canada
229 122. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
230 123. Department of Internal Medicine, Division of Cardiology, National University Hospital of Iceland,
231 Eiríksgata 5, Reykjavik 101, Iceland
232 124. Department of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark
233 125. Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The
234 Netherlands
235 126. Statens Serum Institut, Artillerivej 5, Copenhagen 2300, Denmark
236 127. Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of London,
237 London E1 4AT, England, UK
238 128. Department Life Course and Health, Centre for Nutrition, Prevention and Health Services,
239 National Institute for Public Health and the Environment, Bilthoven, The Netherlands
240 129. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht,
241 The Netherlands
242 130. Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald,
243 Greifswald, Germany
244 131. Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
245 132. Université de Lorraine, CHU de Nancy, Inserm and INI-CRCT (F-CRIN), Institut Lorrain du Coeur
246 et des Vaisseaux, Vandoeuvre Lès Nancy 54500, France
247 133. Duke Clinical Research Institute, Durham, NC 27710, USA
248 134. Duke Molecular Physiology Institute, Durham, NC 27710, USA
249 135. Sections of Cardiology, Preventive Medicine and Epidemiology, Department of Medicine, Boston
250 University Schools of Medicine and Public Health, Boston, Massachusetts, USA,
251 136. Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital,
252 Lund, Sweden
253 137. Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Lund
254 University, Lund, Sweden
255 138. Cardiac Arrhythmia Service and Cardiovascular Research Center, Massachusetts General
256 Hospital, Cambridge, MA, USA
257 139. Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard,
258 Cambridge, MA, USA, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
259 140. Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN, USA
260 141. These authors contributed jointly

261

262

263 **Summary paragraph**

264 Heart failure (HF), a syndrome of symptomatic fluid overload due to cardiac
265 dysfunction, is the most rapidly growing cardiovascular disorder. Despite recent
266 advances, mortality and morbidity remain high and treatment innovation is challenged
267 by limited understanding of aetiology in relation to disease subtypes. Here we harness
268 the de-confounding properties of genetic variation to map causal biology underlying
269 the HF phenotypic spectrum, to inform the development of more effective treatments.
270 We report a genetic association analysis in 1.9 million ancestrally diverse individuals,
271 including 153,174 cases of HF; 44,012 of non-ischaemic HF; 5,406 cases of non-
272 ischaemic HF with reduced ejection fraction (HFrEF); and 3,841 cases of non-
273 ischaemic HF with preserved ejection fraction (HFpEF). We identify 66 genetic
274 susceptibility loci across HF subtypes, 37 of which have not previously been reported.
275 We map the aetiologic contribution of risk factor traits and diseases as well as newly
276 identified effector genes for HF, demonstrating differential risk factor effects on
277 disease subtypes. Our findings highlight the importance of extra-cardiac tissues in HF,
278 particularly the kidney and the vasculature in HFpEF. Pathways of cellular senescence
279 and proteostasis are notably uncovered, including *IGFBP7* as an effector gene for
280 HFpEF. Using population approaches causally anchored in human genetics, we
281 provide fundamental new insights into the aetiology of heart failure subtypes that may
282 inform new approaches to prevention and treatment.

283 **Main**

284 Genome-wide association studies (GWAS) of heart failure (HF) and cardiac traits have
285 begun to yield important translational insights, however, existing studies are limited by
286 phenotypic heterogeneity and a lack of stratification by major aetiologies¹⁻³. To
287 address these limitations, we performed a GWAS meta-analysis of 153,174 HF cases
288 in 1.9 million ancestrally diverse individuals, including analysis of 4 HF subtypes
289 defined by aetiology and left ventricular ejection fraction (**Supplementary Figure 1**).
290 Multimodal definitions were used to harmonise the ascertainment of heart failure
291 (hereafter referred to as HF), non-ischaemic HF (ni-HF), and non-ischaemic HF
292 stratified by left ventricular ejection fraction (LVEF) below or above 50% (ni-HFrEF and
293 ni-HFpEF respectively), together with corresponding control populations. We
294 characterise the common genetic architecture of HF subtypes and use this information
295 to identify the key effector tissues, pathways and genes underlying aetiology. We map
296 the genetic pleiotropy of HF genomic risk loci to identify aetiological phenotype clusters
297 and use Mendelian randomisation to estimate subtype-specific effects of
298 cardiometabolic traits and diseases. These findings provide new insights into the
299 aetiology of HF subtypes and provide a basis for the development of new therapeutic
300 approaches.

301 **Results**

302 **Multi-ancestry genetic association analysis highlights novel heart failure loci**

303 We performed a meta-analysis of case-control GWAS across 42 studies to investigate
304 the association of up to 10,199,961 common genetic variants (minor allele frequency

305 (MAF) >1%) with risk of four HF phenotypes. The study population comprised
306 1,946,349 individuals representing five major ancestry groups: European (86.6%),
307 African (0.8%), South Asian (1.5%), East Asian (10.9%), and Hispanic (0.1%). 153,174
308 HF cases were identified, including 44,012 cases of non-ischaemic HF; 5,406 cases
309 of non-ischaemic HFrEF; and 3,841 cases of non-ischaemic HFpEF (**Supplementary**
310 **Figure 2**). We identified 59 conditionally independent (sentinel) genetic variants at 56
311 non-overlapping genomic loci (distance > 500 kilobase pairs) associated with HF at a
312 genome-wide significance ($P < 5 \times 10^{-8}$) (**Figure 1, Supplementary Table 1**). Sentinel
313 variants showed consistent allelic effects across ancestry groups, except one variant
314 at the *LPA* locus ($P_{het-ancestry} < 0.05 / 59$) (**Supplementary Figure 3, Supplementary**
315 **Table 2**). GWAS of ni-HF, ni-HFrEF, and ni-HFpEF subtypes highlighted 10 additional
316 sentinel variants that were not identified in the HF GWAS. In total, 66 independent
317 genomic risk loci were identified across HF phenotypes^{1,4,5} among which 37 have not
318 previously been reported in GWAS of HF¹⁻⁵. Of the 66 loci, 46 (70%) were associated
319 with at least one of the non-ischaemic HF phenotypes at $P < 0.05 / 66$. These loci were
320 then classified as non-ischaemic HF loci, and the remaining 20 (30%) HF loci were
321 classified as secondary HF (s-HF) loci. Amongst the non-ischaemic loci, 17 were
322 associated with ni-HFrEF and 3 were associated with ni-HFpEF at $P < 0.05 / 66$. In
323 addition, we replicated 76 / 87 (87%) previously reported HF sentinel variants that
324 were available in our study ($P < 0.05 / 87$) (**Supplementary Figure 4, Supplementary**
325 **Table 3**).

326

327 **Genetic architecture and heritability heart failure subtypes**

328 The genetic architecture of HF was found to be highly polygenic, evidenced by an
329 elevated genomic inflation factor ($\lambda_{GC} = 1.22$) in the absence of population stratification
330 (linkage disequilibrium score [LDSC] regression intercept = 1.01) (**Supplementary**
331 **Figures 5-6**), and there was an exponential relationship between allele frequency and
332 effect size for associated variants (**Supplementary Figure 7**). The estimated
333 proportion of variance in disease liability explained by common genetic variants, i.e.
334 SNP-based heritability (h^2_g), was $5.4 \pm 0.2\%$ for HF; $6.1 \pm 0.5\%$ for non-ischaemic HF;
335 $11.8 \pm 2.6\%$ for non-ischaemic HF_{rEF}, and $1.8 \pm 1.3\%$ for non-ischaemic HF_{pEF}
336 (**Supplementary Figure 8**)⁶. All HF phenotype pairs demonstrated positive genetic
337 correlations, with estimates ranging from 0.42 (standard error, SE = 0.18) between ni-
338 HF_{rEF} and ni-HF_{pEF} to 0.93 (SE = 0.15) between ni-HF and ni-HF_{pEF}
339 (**Supplementary Figure 9**). The genetic correlation between ni-HF_{rEF} and both HF
340 (0.66, SE = 0.06) and ni-HF (0.74, SE = 0.06) was lower than for ni-HF_{pEF} (0.85, SE
341 = 0.14 for HF and 0.93, SE = 0.15 for ni-HF), suggesting heritable components that
342 are specific to ni-HF_{rEF}.

343 To explore the potential utility of SNP-based heritability for prediction, we derived a
344 polygenic score (PGS_{HF}) from the HF GWAS excluding UK Biobank (UKB) samples
345 and evaluated the association with HF in UKB. Among 346,667 UKB European
346 participants (13,824 HF cases), the PGS_{HF} was associated with HF (OR per PGS SD
347 1.37 [95% CI 1.27 to 1.46], $P < 2 \times 10^{-16}$) after adjusting for sex, age and first 10
348 genetic principal components (PC)s. Individuals in the top PGS_{HF} decile had a 1.76-
349 fold higher odds of developing heart failure compared to those in the fifth decile (OR
350 = 1.76, 95% CI = 1.64 to 1.89) and 2.89-fold compared to those in the bottom decile
351 (OR = 2.89, 95% CI = 2.66 to 3.14) (**Supplementary Figure 10**).

352

353 **Prioritisation of effector genes for heart failure**

354 To identify HF effector genes, we characterised the functional properties of variants
355 and genes within each identified GWAS locus using a range of orthogonal approaches.
356 Functionally-informed fine-mapping⁷ identified 70 credible sets containing 547 likely
357 causal variants (cumulative posterior inclusion probability > 0.95) at 47/66 HF loci.
358 These credible sets included 11 single nucleotide variants with predicted
359 deleteriousness ranked amongst the top 1% in the reference human genome (CADD
360 Phred score >20)⁸, including exonic variants in established dilated cardiomyopathy
361 (DCM) genes such as *FLNC*, *BAG3* and *HSPB7*⁹⁻¹¹ (**Supplementary Figure 11,**
362 **Supplementary Table 4**).

363 We then prioritised putative causal genes among 758 protein-coding genes
364 overlapping HF loci by triangulating evidence from three predictors of gene relevance:
365 1) variant-to-gene (V2G) score derived from functional properties of fine-mapped and
366 sentinel variants¹², 2) polygenic priority score (PoPS) calculated from enrichment of
367 gene features¹³, and 3) predicted gene expression levels across tissues derived from
368 multi-tissue transcriptome-wide association study (TWAS)¹⁴. 142 genes were ranked
369 by at least one predictor (labelled as *candidate genes*), of which 71 were further
370 prioritised based on: ranking highest on a combined predictor-score; highest ranking
371 with at least two predictors; colocalisation with gene transcript expression in a relevant
372 tissue¹⁵; or association with a phenotypically relevant Mendelian disorder (labelled as
373 *prioritised genes*)¹⁶ (**Figure 2a-c, Supplementary Table 5**).

374 The prioritised genes at secondary HF loci included a high proportion with established
375 evidence linking them to atherosclerotic diseases, for example via regulatory effects
376 on cholesterol and lipoproteins metabolism *LDLR*¹⁷, *LPL*¹⁸, *ABCG5*^{19,20}, *LPA*²¹, and
377 *CDKN2A/CDKN2B*²² (commonly known as 9p21.3 locus). Prioritised genes at the non-
378 ischaemic HF loci included established cardiomyopathy genes *BAG3*, *FLNC*, *ACTN2*,
379 and *HSPB7*,^{9–11,23}, *CAMKD2* (linked to cardiac hypertrophy²⁴), *STRN* (linked to canine
380 DCM²⁵), as well as *PITX2*, *KLF12*, and *ATP1B1* which have been associated with
381 cardiac arrhythmia^{26–28}. Other notable findings include *CAND2*, a muscle-specific
382 gene of which upregulation has been linked to pathological cardiac remodelling²⁹ and
383 *NKX2-5*, a core cardiac transcription factor associated with congenital heart disease
384 and cardiomyopathy^{30–32}.

385 To facilitate genomic appraisal at each identified locus, we constructed an online
386 dashboard visualisation containing regional genetic association, gene prioritisation,
387 cross-trait association, and study-level estimate (**Supplementary Materials**).

388

389 **Biological pathways associated with heart failure subphenotypes**

390 To identify convergent molecular disease mechanisms, we performed a gene set
391 (candidate and prioritised) enrichment analysis. We identified 91 enriched biological
392 pathways and cellular phenotypes for HF and 11 for non-ischaemic HF (adjusted $P <$
393 0.05) (**Figure 3a, Supplementary Table 6**). Several pathways involved in adult tissue
394 homeostasis were identified, including regulation of proteostasis, cellular senescence
395 and extracellular matrix remodelling. Putative effector genes of HF and ni-HF were
396 enriched for proteoglycan pathways, including *ERBB2* the target of cancer therapies

397 that is associated with impaired cardiac function^{33,34}. Genes relating to the formation
398 of aggresomes, cellular organelles store misfolded proteins for subsequent disposal
399 throughautophagy³⁵, were enriched, including *HSBP7* and *BAG3*. *BAG3*-mediated
400 sarcomeric protein turnover is implicated as a mechanism underlying heart failure³⁶.
401 Pathways regulating cell division and senescence were identified, implicating tissue
402 homeostasis and renewal in predisposition to age-associated organ dysfunction,
403 Notably, these included the senescence-associated secretory phenotype, a distinct
404 phenotype with a range of cell-autonomous and non-cell-autonomous effects that re-
405 inforce senescence. *IGFBP7*, a circulating anti-angiogenic factor produced by the
406 kidney and the vasculature, was prioritised within a ni-HFpEF locus. *IGFBP7* was
407 recently reported to stimulate cardiomyocyte senescence and cardiac remodelling³⁷.
408 Pathways related to cardiac arrhythmia, including regulation of cardiac muscle
409 contraction by calcium ion sensing and cell communication by electrical coupling were
410 specifically enriched for ni-HF. The glucocorticoid-related pathways were enriched for
411 all HF subtypes; glucocorticoids are primary stress hormones that are implicated in
412 heart failure through both glucocorticoid and mineralocorticoid receptor-mediated
413 effects³⁸. Genes that were identified in the HF but not the non-ischaemic subtypes
414 were enriched in pathways related to dyslipidaemia.

415

416 **A map of the organs, tissue and cells mediating heart failure risk**

417 To identify tissues and cell types contributing to HF aetiology, we performed a
418 heritability enrichment analysis across 206 tissues and cell types, representing 12
419 organs and systems, using sets of uniquely expressed genes (**Figure 3b**,

420 **Supplementary Table 7**). 46 unique tissues and cell types were enriched (one-sided
421 $P < 0.05$), highlighting the breadth of tissues and organ systems contributing to HF
422 aetiology. Enrichment of cardiac tissues was the most frequent (15 enrichments),
423 followed by musculoskeletal / connective tissues (12 enrichments), and nervous
424 system tissues (8 enrichments). The most highly enriched tissues for HF, ni-HF, and
425 ni-HFrEF, were cardiac whilst the kidney and pancreas were the most highly enriched
426 for ni-HFpEF, highlighting the relative importance of these organs for specific HF
427 phenotypes. Given the importance of cardiac tissues for ni-HFrEF, we extended the
428 resolution of our enrichment analysis to individual cardiac cell populations, using single
429 nucleus gene expression data from 16 non-failing human hearts³⁹ (**Supplementary**
430 **Figure 12a, Supplementary Table 8**). Cardiomyocytes were enriched for non-
431 ischaemic HF and HFrEF subtypes, consistent with the pattern observed in the organ-
432 level analysis.

433 To determine whether HF susceptibility genes were differentially regulated in failing
434 versus non-failing hearts, we investigated cell-type specific expression profiles of the
435 identified HF genes. 30/95 (30%) of ni-HF genes were differentially regulated in failing
436 hearts, predominantly within fibroblasts and cardiomyocytes (**Supplementary Figure**
437 **12b-d, Supplementary Table 9**). Nuclear Receptor Subfamily 3 Group C Member 1
438 (*NR3C1*) which encodes glucocorticoid receptors was upregulated in 12 out of 14
439 cardiac cell types from failing hearts, consistent with the glucocorticoid pathway
440 enrichment among the identified HF genes. These findings support the reported
441 cardioprotective effect of glucocorticoid signalling via inhibition of pathological
442 mineralocorticoid receptor signalling⁴⁰ across human cardiac cell types, which may
443 partially corroborate the unexplained beneficial effect of mineralocorticoid receptor

444 antagonist drugs in HF⁴¹. Another prosurvival HF gene, *KLF12*, was upregulated in
445 cardiomyocytes and cardiac fibroblasts. KLF12 is a transcription factor that is
446 upstream of p53 and p21 (*CDKN1A*); methylation of the KLF12 transcription factor
447 binding motif has been identified as a mechanism for *LMNA* cardiomyopathy⁴². In
448 contrast to prior reports, we did not observe differential expression of *IGFBP7* in
449 cardiomyocytes from failing hearts³⁷.

450

451 **Graph modelling of phenome-wide pleiotropy identifies aetiologic clusters**

452 To identify aetiological clusters underlying HF based on shared genetic aetiology, we
453 tested the associations between sentinel variants at the 66 HF susceptibility loci and
454 294 diseases in UK Biobank, and modelled the associations using a pleiotropy network
455 graph⁴³. We found 207 pleiotropic associations at FDR <1% (corresponding to $P <$
456 0.001) among 46 / 66 (70%) HF loci and 79 / 294 (27%) unique phenotypes
457 (**Supplementary Figures 13-14, Supplementary Table 10**). We constructed a HF
458 pleiotropy graph network by representing loci and diseases as nodes and locus-
459 phenotype associations as edges (**Supplementary Figure 15a**). Community
460 detection analysis on the network revealed distinct 18 locus-disease aetiological
461 clusters (**Figure 4, Supplementary Figure 15b, Supplementary Table 11**). The
462 largest cluster, cluster 1, contained traits and diseases related to atherosclerosis and
463 genes that were predominantly related to secondary HF loci. Cluster 2 comprised
464 cardiac arrhythmias and dilated cardiomyopathy, and genes mostly associated with
465 non-ischaemic HF. Cluster 4 centred on hypertension but contained genes for infection

466 and cancer, while Cluster 5 comprised genes associated with non-ischaemic HF and
467 ni-HFpEF, and disease including adiposity, diabetes, and carpal tunnel syndrome.

468 Given the extensive pleiotropic effects of HF susceptibility loci, we further investigated
469 the effects of sentinel variants in each locus on 24 GWAS traits representing major
470 organ systems and image-based cardiac endophenotypes. We identified 270
471 genotype-phenotype associations at FDR <1%, of which 95 (35%) reached genome-
472 wide significance in the original GWAS (**Supplementary Figure 16, Supplementary**
473 **Table 12**). All tested traits were associated with at least one HF locus at FDR <1%,
474 with coronary artery disease (CAD) and systolic blood pressure (SBP) showing the
475 highest number (25 out of 66 loci / 38%). All lead variants in HF loci that were
476 associated with DCM (6 loci) showed a concordant allelic effect (i.e. additional HF risk-
477 increasing allele was associated with an increased disease risk), whereas all shared
478 associations with HCM (14 loci) showed a discordant allelic effect, consistent with the
479 opposite genetic effects on both traits⁴⁴. Colocalisation analysis revealed evidence of
480 105 common causal variants across 22 of the 24 traits tested (posterior probability >
481 0.8) at 42 out of 66 loci (**Figure 5a-c, Supplementary Table 14**), adding further
482 evidence for pleiotropic associations and unveiling novel associations. For example,
483 we found colocalisation of the *BACH1* ni-HFrEF locus with both coronary artery
484 disease and dilated cardiomyopathy. *BACH1* is a transcription factor expressed in
485 cardiac fibroblast and endothelial cells in response to mechanical stress and regulates
486 YAP⁴⁵. The BACH1-YAP transcriptional network exerts essential roles in both
487 atherosclerosis and cardiac regeneration through the regulation of proliferative
488 programs in cardiomyocytes⁴⁶. Notably, six HF genes were found to colocalise with
489 glomerular filtration rate (eGFR) or chronic kidney disease (CKD), including prefoldin

490 subunit 1 (*PFDN1*) an important molecular chaperone for protein folding associated
491 with mortality and cardiovascular phenotypes in mouse knockouts^{47,48}.

492

493 **Genetic appraisal of risk factors across the heart failure spectrum**

494 Next, we sought to explore evidence for causal relationships between risk phenotypes
495 associated with HF in the pleiotropy analysis, using genetic correlation and Mendelian
496 randomisation (MR) analysis (**Figure 6, Supplementary Figure 17-19,**
497 **Supplementary Tables 14-15**). First, we compared the estimated effects of upstream
498 risk factors on HF and non-ischaemic HF. Trait associations were broadly similar
499 between HF and ni-HF, except for coronary artery disease (CAD) for which there was
500 evidence of causal effects on HF [MR odds ratio per doubling prevalence with inverse
501 variance weighted estimator / $OR_{MR-IVW} = 1.20$, 95% confidence intervals = 1.18-1.22]
502 but not on non-ischaemic HF [$OR_{MR-IVW} = 1.02$, 1.00-1.04]. We found evidence for the
503 causal effects of systolic blood pressure (SBP), body mass index (BMI), and liability
504 to atrial fibrillation (AF) across the HF phenotypic spectrum. SBP had the largest effect
505 on ni-HFrEF [$OR_{MR-IVW} = 1.92$, 1.70-2.17 per standard deviation / SD] while BMI had
506 the largest effects on ni-HFpEF [$OR_{MR-IVW} = 1.87$, 1.70-2.06 per SD]. Although type 2
507 diabetes and HF shared ~23% genetic risk [squared genetic correlation / $r_g^2 = 0.23$],
508 there was little evidence of a causal association between the two disorders [OR_{MR-IVW}
509 = 1.04, 1.03-1.05; $OR_{MR-Egger} = 0.98$, 0.96-1.00 per doubling prevalence], suggesting
510 that observational associations between T2D and HF largely reflect common upstream
511 disease mechanisms, rather than direct causal effects of T2D on HF. Higher functional
512 lung capacity (forced vital capacity, FVC; forced expiratory volume in 1 second, FEV1)

513 was protective for HF [$OR_{MR-IVW} = 0.93$, 0.87-0.94 per SD FVC; $OR_{MR-IVW} = 0.87$, 0.83-
514 0.92 per SD FEV1] and ni-HFpEF [$OR_{MR-IVW} = 0.70$, 95% CI = 0.61-0.80 per SD FVC;
515 $OR_{MR-IVW} = 0.86$, 0.76-0.97 per SD FEV1]. We found evidence for effects of smoking
516 behaviour on HF [$OR_{MR-IVW} = 1.26$, 95% CI = 1.19-1.33 per SD pack-years of smoking].
517 Positive associations of higher alcohol consumption with HF [$OR_{MR-IVW} = 1.17$, 95%
518 CI = 1.06-1.29 per SD drinks / week] and ni-HFrEF [$OR_{MR-IVW} = 1.87$, 95% CI = 1.37-
519 2.55 per SD drinks / week] were observed, consistent with clinical studies relating
520 alcohol consumption to DCM⁴⁹.

521 Although renal tissues and traits (glomerular filtration rate, eGFR; chronic kidney
522 disease, CKD) were associated with ni-HFpEF in the heritability enrichment (**Figure**
523 **4**) and colocalisation analyses (**Figure 6**), we found little or no evidence of genetic
524 correlation [$r_g = 0.17$, SE = 0.05 between HF and CKD; and $r_g = -0.001$, SE = 0.052
525 between HF and eGFR]. These findings may reflect directional heterogeneity of locus-
526 specific effects which results in a global genetic correlation. For example, there were
527 13 lead variants of HF associated with eGFR at FDR 1%, of which 8 had a concordant
528 allelic effect and 5 had a discordant allelic effect on HF risk (**Supplementary Figure**
529 **16**). Paradoxically, we found suggestive evidence of a protective effect of CKD on ni-
530 HFpEF [$OR_{MR-IVW} = 0.89$, 0.81-0.98] which may indicate confounding by competing
531 diagnosis, whereby a CKD diagnosis reduces the likelihood of diagnosis with HF in
532 patients presenting with fluid congestion⁵⁰.

533

534 **The relationship between cardiac structure and function and heart failure**

535 Traits and diseases associated with reduced contractile function were found to be
536 associated with risk of all HF phenotypes, except ni-HFpEF (**Figure 6,**
537 **Supplementary Figure 19**). As expected, the strongest effect was observed in ni-
538 HFpEF [$OR_{MR-IVW} = 0.18$, 0.12-0.27 per SD LVEF; $OR_{MR-IVW} = 1.83$, 1.64-2.03 per
539 doubling prevalence of DCM]. Conversely, traits associated with increased contractility
540 were protective of ni-HFpEF [$OR_{MR-IVW} = 0.88$, 0.85-0.91 per doubling prevalence of
541 HCM] and suggestive evidence that higher left ventricular ejection fraction is a risk
542 factor for ni-HFpEF was observed [$OR_{MR-IVW} = 1.28$, 0.99-1.67 per SD LVEF]. These
543 findings are consistent with divergent risk effects of subnormal and supranormal
544 contractility DCM / HFpEF and HCM / HFpEF^{44,51}. Despite the widely held hypothesis
545 that diastolic dysfunction is the key driver for HFpEF, we found inconsistent evidence
546 to support a causal association [OR_{MR-IVW} for ni-HFpEF = 1.16, 0.91-1.48 per SD
547 PDSR-r].

548 **Discussion**

549 The processes of evolution to animal life on land led to exquisite systems of body
550 water regulation but an inherent susceptibility to systemic and pulmonary oedema⁵².
551 Syndromes of fluid overload are a common clinical problem described since antiquity
552 and are associated with elevated morbidity and mortality⁵³. In the 20th century, cardiac
553 dysfunction was identified as an important cause of fluid overload and formed the basis
554 for the definition of heart failure. Increasingly, however, the importance of non-cardiac
555 tissue in HF aetiology is emerging. By leveraging the de-confounding properties of
556 germline genetic variation, we systematically appraise the aetiology of HF, highlighting

557 key phenotypic traits, tissue, pathways and genes. Our findings generate new insights
558 into the drivers of risk in particular HF subtypes, including for patients with preserved
559 ejection fraction where therapeutic options are limited.

560 The insights from our study have several important translational implications. First, our
561 appraisal of cardiovascular risk factor effects on HF subtypes yields several notable
562 findings. Whilst clear effects of epicardial CAD and T2D on HF were observed, no
563 effect on HF patients who had not undergone revascularisation or suffered from
564 myocardial infarction was identified. Similarly, while T2D and HF share common
565 genetic and environmental risk factors, we did not find strong evidence supporting a
566 causal association between T2D and HF. These findings highlight the importance of
567 managing upstream risk factors for diabetes and CAD, for the prevention of HF.
568 SGLT2 inhibitors may exert their beneficial effects on HF risk and progression through
569 modification of upstream physiology for both T2D and HF⁵⁴, such as higher body mass
570 index; the effects of which are consistent across subtypes and may be independent of
571 established risk factors⁵⁵.

572 Second, our findings highlight the importance of cardiac contractility traits in HF. Non-
573 ischaemic HFrEF was the most heritable subtype ($h^2_{\text{SNP}} = 11.8\% \pm 2.6\%$) and was
574 highly correlated with DCM ($r_g = 0.57 \pm 0.12$), as expected. We demonstrate opposing
575 associations between contractility-related traits and ni-HFrEF and ni-HFpEF risk:
576 higher baseline contractility decreased the risk of HFrEF, but likely increased the risk
577 of HFpEF. Our findings do not provide positive evidence to support the widely held
578 hypothesis that diastolic function is the major cause of HFpEF.

579 Third, our heritability enrichment analysis suggests that kidney, vascular, and
580 metabolic tissues play a central role in the aetiology of HFpEF. The kidney is the
581 primary organ for managing body fluid, and renal impairment is common in heart
582 failure patients across the phenotypic spectrum. CKD, however, co-occurs more
583 frequently with HFpEF than HF with mid-range or reduced ejection fraction⁵⁶. It is
584 possible that suggestive evidence of a paradoxical protective effect of CKD on ni-
585 HFpEF reflects these diagnoses being alternative diagnoses for overlapping or
586 indistinguishable clinical presentations. These findings motivate future studies to
587 further investigate extra-cardiac drivers of fluid congestion in this patient population.

588 Fourth, our results reveal novel molecular mechanisms, both cardiac and extracardiac,
589 across the heart failure spectrum. Tissue homeostasis emerges as a major
590 mechanism underlying risk across the phenotypic spectrum of heart failure. Cell
591 intrinsic mechanisms, including through modulation of *BACH1-YAP*, *KLF12-CDKN1A*
592 activity, may influence myocardial tissue homeostasis through effects on cardiac
593 growth. We found enrichment of the senescence-associated secretory phenotype
594 components in pathway analysis and identify *IGFBP7* as a novel prioritised HFpEF
595 gene, reflecting cell-autonomous effects of senescent cells on organismal aging⁵⁷.
596 *IGFBP7* is synthesised by the vasculature in response to tissue damage and may be
597 an upstream driver of cell cycle arrest, fibrosis, and vascular rarefaction that are
598 observed in HFpEF. *IGFBP7* is an established clinical biomarker of acute renal failure
599 and may represent a target for novel therapeutics^{37,58}.

600 In summary, by harnessing the de-confounding qualities of human germline variation,
601 we map the aetiology of the heart failure spectrum, from organs to molecules. Our
602 findings provide genetic evidence to bolster the concept of HFpEF as a multi-system

603 disorder and yield insights into the biological mechanisms underlying subtypes of HF
604 that may inform the development of more effective therapeutics to improve outcomes
605 in those affected.

606

607

608

609 **Online Methods**

610 **Study design**

611 The present meta-analysis included 1,946,349 individuals from 42 studies
612 participating in the HERMES Consortium (40 studies) or publicly released GWAS data
613 of heart failure (Biobank Japan and FINNGEN r3). Sample genotyping was performed
614 locally per study per phenotype per ancestry (one dataset) using high-density
615 genotyping arrays and imputed against Haplotype Reference Consortium⁵⁹ (75
616 datasets), 1000 Genomes Project⁶⁰ (6 datasets), TOPMED⁶¹ (15 datasets), or
617 population-specific reference panels (10 datasets).

618 Study-level GWAS was performed locally per dataset using logistic regression (for
619 prevalent cases) or cox proportional hazard (for incident cases) assuming additive
620 genetic effect with adjustment for sex, age at DNA draw, genetic principal components,
621 and study-specific covariates. All participating studies were ethically approved by local
622 institutional review boards and all study participants provided written informed
623 consent. The meta-analysis was performed centrally at the coordinating centre in
624 accordance with guidelines for study procedures provided by the University College
625 London Research Ethics Committee. Details of study-level participant characteristics,
626 genetic analysis, and cohort description are provided in **Supplementary Tables 16-**
627 **18.**

628 **Phenotype definition**

629 The present analysis investigated 4 phenotypes: 1) Heart failure (HF), 2) Non-
630 ischaemic HF (ni-HF), 3) Non-ischaemic HFrEF (ni-HFrEF), and 4) Non-ischaemic
631 HFpEF (ni-HFpEF). The HF phenotype includes any diagnosis of HF based on
632 physician's adjudication, hospital record review, or diagnosis codes. Non-ischaemic
633 HF was defined by excluding antecedent ischaemic, valvular, and congenital heart
634 diseases. Non-ischaemic HFrEF was defined as non-ischaemic HF with LVEF <50%
635 based on cardiac imaging or diagnosis of left ventricular systolic dysfunction (LVSD)
636 at any point. Non-ischaemic HFpEF was defined as non-ischaemic HF with LVEF
637 $\geq 50\%$ based on cardiac imaging without record of LVSD at any point. Phenotyping
638 was performed separately in each participating study, using a harmonised multi-modal
639 phenotyping algorithm (**Supplementary Note**) as a guide. Phenotype definition for
640 FINGENN (release 3)⁶² and Biobank Japan⁶³ follows the original study case definition.
641 Details of study-level phenotype definition are provided in **Supplementary Table 19**.

642

643 **Study-level summary statistics quality control**

644 GWAS summary statistics from each participating study were processed centrally with
645 a quality control (QC) workflow implemented in *Snakemake*⁶⁴ following the procedure
646 described by Winkler T, *et al*⁶⁵. Variants with more than two alleles, regression
647 coefficients (log odds ratio or log hazard ratios) >10, standard error of the coefficients
648 >10, minor allele frequency (MAF) <1%, imputation (INFO) score <0.6, or effective
649 allele count (, calculated as $2 \times MAF \times (1 - MAF) \times N_{sample} \times INFO$, of <50 were
650 excluded from the analysis. Remaining variants with allele frequency difference >0.2

651 as compared against ancestry-specific reference panels were further excluded. The
652 reference panels were derived from whole-genome sequence data from HRC and
653 1000 genomes project phase 3 version 5 (1000Gp3v5) for European ancestry, or
654 1000Gp3v5 for East Asian, South Asian, African, and Admixed American (Hispanic)
655 ancestries. Genomic inflation adjustment was applied for summary statistics with
656 genomic control coefficient (λ_{GC}) > 1.1 . In addition, the reported P values and quantile-
657 quantile (QQ) plots from all studies were inspected to check for consistency and to
658 identify spurious associations. Full details of the quality control procedure and results
659 are provided in **Supplementary Materials**.

660

661 **Genome-wide association meta-analysis**

662 Study-level GWAS results were meta-analysed using a fixed-effect inverse variance
663 weighted model implemented in METAL⁶⁶. For each phenotype, we calculated variant-
664 level and summary-level effective sample size as $4 / (1/N_{case} + 1/N_{control})$ where
665 N_{case} and $N_{control}$ represent the number of cases and controls included in the meta-
666 analysis. Variants with an estimated overall MAF < 0.01 , variant-level effective sample
667 size $< 10\%$ of the meta-analysis effective sample size, or reported in only one study
668 were further removed. The final results consist of genetic association estimates of
669 10,199,961 common genetic variants (MAF $> 1\%$) with HF; 9,414,975 variants with
670 non-ischaemic HF; 9,198,919 variants with non-ischaemic HFrEF; and 8,277,415
671 variants with non-ischaemic HFpEF.

672

673 **Cross-ancestry allelic effect heterogeneity assessment**

674 To account for a possible bias due to heterogeneity of allelic effect across ancestries,
675 we performed a sensitivity analysis using a meta-regression technique to model
676 ancestry-specific allelic effect by incorporating axes of genetic variation derived from
677 genome-wide metrics of diversity between populations, as implemented in MR-
678 MEGA⁶⁷. Using this technique, we also estimated overall *P* value for associations
679 accounting for allelic effect heterogeneity across ancestries, *P* value for heterogeneity
680 correlated with ancestry, and *P* value for residual heterogeneity. Concordance
681 between *P* values from the fixed-effect meta-analysis with METAL and those from MR-
682 MEGA were checked by calculating Pearson's correlation coefficient and plotting the
683 two vectors on a two-dimensional plane across conditionally independent variants.
684 Given the limited non-European ancestry sample for non-ischaemic HF subtypes, this
685 comparison was only performed using the overall HF phenotype.

686

687 **Identification of genomic susceptibility loci across HF subtypes**

688 Genomic susceptibility loci for HF were identified using sets of conditionally
689 independent variants identified through a chromosome-wide stepwise conditional-joint
690 analysis using Genome-wide Complex Trait Analysis (GCTA) software⁶⁸. Conditionally
691 independent variants across 4 HF phenotypes with joint *P* value $< 5 \times 10^{-8}$ that are
692 physically located within 500 kilobases of each other were aggregated into one set. A
693 genomic locus was then defined as the genomic region within 500 kilobases upstream
694 and downstream of the farthest variants of each aggregated set of conditionally
695 independent variants.

696 The identified genomic loci were labelled with an incremental one-based integer
697 sequence based on phenotype order (HF, ni-HF, ni-HFrEF, and ni-HFpEF),
698 chromosome, and base pair positions. A genomic locus was declared as novel if all
699 conditionally independent variants within the locus and any of the sentinel variants
700 reported at $P < 5 \times 10^{-8}$ in previous GWAS of HF¹⁻⁵ were physically located more than
701 250 kb away and not in LD ($R^2 < 0.2$). To model LD between genetic variants, we
702 used a reference panel derived from individual-level imputed genotype data of a
703 randomly sampled 10,000 UK Biobank participants with an ancestry composition
704 proportionally matched to the present meta-analysis (Hispanic ancestry was not
705 included due to unavailability in UK Biobank and small proportion in the overall
706 sample).

707 Further, association between a locus and a HF subtype was categorised based on P
708 values at cut-off values of $P < 5 \times 10^{-8}$ (genome-wide significant), $P < 0.05 / \text{number}$
709 of identified loci (replicated at Bonferroni-adjusted threshold), $P < 0.05$ (nominally
710 significant), and $P \geq 0.05$ (no evidence of association). For presentation, loci
711 associated with any non-ischaemic HF subtype at Bonferroni-adjusted or genome-
712 wide significance thresholds were labelled as non-ischaemic HF loci, and the
713 remainings were labelled as secondary HF loci. Non-ischaemic HF loci that are
714 associated with ni-HFrEF at Bonferroni-adjusted or genome-wide significance
715 thresholds were labelled as ni-HFrEF loci, and the remainings were labelled as ni-
716 HFpEF loci.

717

718 **Genetic architecture assessment**

719 To assess genetic architecture and polygenicity across HF phenotypes, we compared
720 quantiles of the expected and observed genome-wide genetic association P -values
721 using quantile-quantile (QQ plot) and calculated genomic control coefficient (λ_{GC}). An
722 early inflation on QQ plot with $\lambda_{GC} > 1.1$ suggests genome-wide genomic inflation,
723 which may be due to polygenic genetic architecture or confounding by population
724 stratification. To distinguish between the two, we calculated λ_{GC} assuming 1000
725 participants ($\lambda_{GC-1000}$), and estimated LD score regression slope using LDSC
726 software⁶⁹, whereby values close to 1 indicate that any observed genomic inflation is
727 likely due to polygenic genetic architecture. To minimise confounding by population
728 structure, LDSC regression was performed using European ancestry meta-analysis
729 subset and LD reference panel. We investigated the distribution of allelic effect on HF
730 across the spectrum of allele frequency by plotting the risk ratio per additional minor
731 allele as a function of minor allele frequency of conditionally independent variants. To
732 assess the shape of the relationship, we fitted two separate local polynomial
733 regression with locally estimated scatterplot smoothing (LOESS) for groups of variants
734 associated with increased and decreased risk of HF. To increase precision of the fitted
735 regression, a sub-genome-wide threshold association at a false discovery rate (FDR)
736 $<1\%$, estimated using the *qvalue* package in R⁷⁰, was used to identify conditionally
737 independent variants.

738

739 **SNP-based heritability estimation**

740 The proportion of variance in HF risk explained by common SNPs, i.e. SNP-based
741 heritability (h_{SNP}^2), was estimated from GWAS meta-analysis summary statistics using
742 Linkage-Disequilibrium Adjusted Kinships (LDAK) SumHer software⁷¹ with LDAK-Thin
743 and BLD-LDAK heritability models⁷². The h_{SNP}^2 estimates were calculated on a liability
744 scale, which assumes that a binary phenotype has an underlying continuous liability,
745 and above a certain liability threshold an individual becomes affected⁷³. To obtain a
746 more accurate estimate, we used the European ancestry meta-analysis summary
747 statistics with pre-computed tagging files derived from 2,000 individuals White British
748 individuals, and used a correction for sample prevalence by calculating the effective
749 sample size assuming an equal number of cases and controls⁷⁴. The conversion to
750 liability scale was calculated using population prevalence derived from the total
751 number of cases divided by the total number of cases and controls included in the
752 meta-analysis.

753

754 **Polygenic risk score analysis**

755 To explore the potential utility of SNP-based heritability for prediction, we explored the
756 association between polygenic score of HF (PGS_{HF}) and HF risk in 346,667 UKB
757 European participants, including 13,824 prevalent and incident HF cases. The PGS_{HF}
758 was constructed as a weighted sum of allelic count of 1,012,059 genetic variants
759 selected using the LDpred2-auto model⁷⁵, with weights derived from the present

760 GWAS meta-analysis of HF excluding UK Biobank. Odds ratio of HF per standard
761 deviation of PGS_{HF} was estimated using logistic regression with binary HF status as
762 response variable, standardised PGS_{HF} as predictor, and sex, age and first 10 ten
763 genetic principal components (PC)s as covariates. To estimate risks of HF in
764 individuals with high PGS_{HF} , we grouped participants into deciles of PGS_{HF} , and
765 calculated odds ratios of the top decile as compared against the fifth and the first
766 (bottom) decile using logistic regression.

767

768 **Fine mapping of causal variants and functional assessment**

769 We performed functionally-informed fine-mapping using PolyFun⁷ and SuSiE⁷⁶ to
770 prioritise likely causal variants in each identified genomic locus for HF. We used
771 precomputed functionally-informed prior causal probabilities of 19 million imputed UK
772 Biobank SNPs with $MAF > 0.1\%$, based on a meta-analysis of 15 UK Biobank traits⁷
773 and genome-wide association estimates from the current analysis to calculate prior
774 causal-probability proportional to per-SNP heritability of phenotype under analysis.
775 The resulting estimates were passed on to the sum-of-single-effects fine-mapping
776 model implemented in SuSiE, assuming at most 5 causal variants per locus, to
777 calculate per-SNP posterior inclusion probability (PIP) and to construct 95% credible
778 sets of likely causal variants. To minimise bias due to differential ancestry composition,
779 we used effect estimates from meta-analysis of European ancestry GWAS and LD
780 reference panel from 10,000 randomly selected UK Biobank participants of European
781 ancestry. To assess functions and consequences of fine-mapped variants, we
782 extracted variant-level information on nearest gene(s), genic functions, and Combined

783 Annotation-Dependent Depletion (CADD)⁸ Phred score from ANNOVAR⁷⁷ and
784 OpenTargets Genetics¹².

785

786 **Prioritisation of effector genes for HF**

787 To identify effector genes for HF, we implemented a two-step in silico gene
788 prioritisation approach. In step 1, we identified *candidate* gene set using a combination
789 of three *predictors*:

790 1. Polygenic priority score (PoPS)

791 Polygenic enrichment of gene features derived from cell-type specific gene
792 expression, biological pathways, and protein-protein interactions¹³

793 2. Variant to gene score (V2G)

794 Highest V2G score across variants in the 95% credible set and variants in high
795 LD ($r^2 > 0.8$) with the conditionally independent variants within the locus. The
796 V2G score was extracted from the OpenTargets Genetics^{12,78}, and was derived
797 from in silico functional prediction, expression and protein quantitative trait loci,
798 chromatin interactions, and distance to gene's canonical transcription start site
799 portal

800 3. Transcriptome-wide association study (TWAS)

801 *P* value for association of overall predicted gene expression across tissues with
802 HF calculated using S-MuTIXcan¹⁴ with GTEX⁷⁹ v8 MASHR models.

803 Genes with highest PoPS, highest V2G score, or lowest TWAS *P* value within a locus
804 were considered as *candidate* effector genes for HF. In step 2, we prioritised these
805 genes using 3 boolean (True / False) *classifiers*:

806 1. Top ≥ 2

807 Whether a gene ranked top by 2 of the 3 *predictors* (PoPS, V2G, TWAS)

808 2. Mendel

809 Whether a gene is associated with at least one Mendelian disease term that is
810 enriched at FDR <1% as estimated from Mendelian gene set enrichment
811 analysis using MendelVar¹⁶.

812 3. Coloc

813 Whether gene expression level in tissue with lowest *P*-value from the multi-
814 tissue TWAS analysis colocalised with at least 1 HF phenotype under study
815 (posterior probability of shared causal variants >0.8). The colocalization
816 analysis was performed with the R *coloc* package allowing for multiple causal
817 variants¹⁵ using gene expression data from GTEx v8⁷⁹.

818 In addition, we derived an *Overall* predictor score based on weighted average of
819 PoPS, highest V2G, and $-\log_{10} P$ MultiXcan values with 2:2:1 weight ratio, scaled to
820 0-100 value using a quantile transformation with uniform output distribution as
821 implemented in python *scikit-learn*⁸⁰ library. Finally, for each locus, we ranked genes
822 based on total classifier score (sum of *True* values) and the overall predictor score.
823 Genes that are top-ranked or have a total classifier score ≥ 2 were *prioritised* as most
824 likely effector genes for HF.

825 Analyses which require GWAS summary statistics (PoPS, TWAS, and Coloc) were
826 performed separately for each of the 4 HF phenotypes using meta-analysis results
827 from the European subset. Locus-specific results for gene prioritisation were extracted
828 from the overall HF phenotype for loci with $P_{HF-GWAS} < 5 \times 10^{-8}$ (locus 1-56), or from
829 HF phenotype with the lowest $P_{GWAS} < 5 \times 10^{-8}$ for subtype-specific loci (ni-HF for locus
830 57-61, ni-HFrEF for locus 62-64, ni-HFpEF for locus 65-66).

831

832 **Heritability enrichment analysis**

833 To identify relevant tissues and cell types involved in HF pathology, we estimated
834 heritability enrichment of specifically expressed genes using LDSC-SEG⁸¹. We used
835 specifically expressed gene sets for 206 tissues and cell types from GTEx and Franke
836 Lab^{82,83}, classified into 12 organ / system categories (**Supplementary Table 20**). For
837 each set, LDSC-SEG tested the enrichment for per-SNP heritability attributed to the
838 given set, conditional on the set that includes all genes and a baseline model
839 consisting of 52 genomic annotations (including genic regions, enhancer regions and
840 conserved regions) using stratified LDSC regression framework⁸⁴. A positive
841 regression coefficient, statistically tested using a one-sided *P*-value test, represents a
842 positive contribution of a given tissue / cell type to trait heritability. For this analysis,
843 we used the European ancestry meta-analysis subset with pre-computed LD score
844 weights derived from the 1000 Genomes European reference panel⁸⁴.

845 Further, based on the observation that heart tissues are the major contributors to SNP
846 heritability in almost all HF phenotypes, we extended the heritability enrichment
847 analysis to 15 cell types derived from single-nucleus RNA sequencing (snRNA-seq)
848 experiment on 185,185 cell nuclei from 16 non-failing human heart donors³⁹
849 (**Supplementary Table 21**). To identify specifically expressed genes for each cell
850 type, we followed the approach described in Finucane et al. (2018)⁸¹ by taking top
851 10% genes with the highest *t*-statistic for specific expression in a given cell type
852 (compared to other cell types). The sets of specifically expressed genes for each
853 cardiac cell type were used to perform the heritability enrichment analysis with LDSC-
854 SEG as described above.

855

856 **Single-nucleus differential gene expression in failing vs. non-failing heart**

857 To assess the extent to which transcriptional pattern of risk genes for HF changes in
858 failing heart, we performed single-nucleus differential gene expression analysis of
859 candidate effector genes within HF loci by comparing transcription level in cell nuclei
860 from non-failing heart as described above with cell nuclei from 28 failing heart donors
861 diagnosed with end-stage dilated cardiomyopathy (DCM) or hypertrophic
862 cardiomyopathy (HCM)³⁹.

863 Samples were collected from Myocardial Applied Genetics Network (MAGNet;
864 www.med.upenn.edu/magnet), with snRNA-seq processed using CellBender⁸⁵ and
865 Cell Ranger⁸⁶ as previously described^{39,87,88}. Where available, for each gene in a given
866 cell type, we computed statistics for differential gene expression between failing and
867 non-failing samples using limma–voom^{89,90} model adjusting for age and sex. To
868 account for the correlation in expression among nuclei from a given individual, we
869 summed counts for genes across nuclei for each patient within each cell type, requiring
870 a minimum of 25 nuclei. We excluded mitochondrial genes and ribosomal genes,
871 removed genes in less than 1% of nuclei in the given cell type of both groups being
872 compared, and applied an additional filter for lowly expressed genes using the
873 `filterByExpr(group=group)` function. Two-sided P-values were calculated and A
874 Benjamini–Hochberg correction was applied for multiple testing correction.

875 A gene was declared to be differentially expressed if it survived multiple-testing
876 correction at FDR-adjusted P-value <0.01 and showed a concordant differential
877 expression sign in both CellBender and Cell Ranger quantifications and had no

878 background contamination as estimated in CellBender. To test whether differentially
879 expressed genes in a given cell type are overrepresented amongst prioritised HF
880 genes, we performed a Fisher exact test implemented in *R*, using all genes tested in
881 the given cell type as the background set.

882

883 **Pathway enrichment analysis**

884 To identify biological pathways and processes that are relevant to HF pathology, we
885 tested for overrepresentation of biological terms in prioritised genes for HF using
886 g:Profiler⁹¹. To account for aetiological differences underlying HF subtypes and
887 uncertainty in gene prioritisation, we tested 6 gene sets constructed from combinations
888 of 3 phenotypic classifications of loci (all loci, secondary HF loci, non-ischaemic HF
889 loci); and 2 gene prioritisation categories (*Candidate* gene set: genes that are ranked
890 top by PoPS, TWAS, or V2G predictor and *Prioritised* gene set: candidate genes with
891 classifier score ≥ 2 or highest overall predictor score). For each gene set, we performed
892 an unordered enrichment analysis of biological terms in Kyoto Encyclopedia of Genes
893 and Genomes (KEGG)⁹², Reactome (REAC)⁹³; Wiki Pathways (WP)⁹⁴; and Gene
894 Ontology (GO)^{95,96}. For presentation (**Figure 3a**), we excluded terms with more than
895 2,000 genes (representing $\sim 10\%$ of protein coding genes in the human genome) and
896 included terms with adjusted $P < 0.05$ following g:Profiler correction for multiple testing.
897 GO terms were summarised by highlighting only driver terms as identified by the
898 g:Profiler clustering algorithm. Terms that are enriched in both *candidate* and
899 *prioritised* gene sets were collapsed by presenting the median enrichment P value on
900 $-\log_{10}$ scale.

901

902

903 **Phenome-wide association studies in UK Biobank**

904 To characterise pleiotropic effects of HF genetic loci across human diseases, we
905 performed a phenome-wide association study (PheWAS) by testing the associations
906 of the lead variants at 66 HF loci with 294 disease phenotypes in 408,480 UK Biobank
907 participants of European ancestries. Phenotypes were derived from clinical events
908 recorded in data from linked hospital admission, death certificate, primary care visit,
909 and self-reported cancer diagnosis, non-cancer diagnosis, and procedure history;
910 using expert-curated phenotype definition and category described elsewhere⁴³. For a
911 given phenotype, participants were classified as cases if they ever had a record of at
912 least one matching code in any data source; otherwise as controls. For each
913 phenotype - lead variant pair, we ran a case-control genetic association analysis
914 implemented in PLINK2, requiring at least 100 cases and 100 controls per phenotype.
915 The association analysis was performed using a logistic regression model assuming
916 an additive allelic effect and adjusted for sex, genotyping array, and first ten genetic
917 principal components. For presentation, allelic effect estimates were aligned to
918 represent the effect of one additional HF risk-increasing allele.

919

920 **Pleiotropy network analysis**

921 Using results from the identified genotype-phenotype associations from the locus
922 PheWAS, we performed a network analysis to evaluate the connections between HF
923 genetic loci based on their pleiotropic effects across human diseases. First, we

924 constructed a network dataset with nodes (vertices) representing loci or phenotypes;
925 and edges representing unidirectional associations of the locus lead variant with a
926 given phenotype. The resulting network was then visualised using the Davidson-Harel
927 layout algorithm⁹⁷. To help with interpretation, edges on the graph were coloured by
928 the effect direction of HF risk-increasing allele, with thickness of the line representing
929 absolute Z statistics for the association. Phenotype nodes were labelled by disease
930 name and coloured by disease category; whereas locus nodes were labelled by most
931 likely effector genes. Eigenvector centrality measure was calculated to estimate node
932 influence within the network (**Supplementary Figure 20, Supplementary Table 22**),
933 and then mapped to the node size so that a more influential node appears larger.

934 Further, we performed a data-driven community detection analysis on the graph using
935 a walktrap algorithm⁹⁸ weighted by absolute Z score of the edges to identify clusters
936 of densely connected nodes. Overall modularity⁹⁹ of the resulting clusters was
937 calculated to quantify the strength of the division, where a higher value reflects a
938 connection between nodes that is denser for nodes within the same cluster but sparser
939 for nodes belonging to different clusters. The network analysis and visualisation was
940 performed using the *igraph*, *tidygraph* and *ggraph* package in R.

941

942 **Locus-specific pleiotropy assessment**

943 We investigated the local pleiotropic effects of sentinel variants in 66 genetic loci on
944 24 HF-relevant GWAS traits (**Supplementary Table 23**). Sentinel variants were
945 defined as conditionally independent variants showing lowest *P*-value for association
946 with HF phenotypes within a locus. For loci associated with both all-comer HF and at

947 least one non-ischaemic HF phenotype, sentinel variants were taken from all-comer
948 HF. Estimates for sentinel variant that were not reported in a target GWAS were
949 substituted with those of a proxy variant with highest LD r^2 (requiring at least LD r^2
950 >0.8), identified using *plink*¹⁰⁰ with LD reference panel derived from 10,000 random
951 samples of UK Biobank European participants. For presentation (**Supplementary**
952 **Figure 15**), effect estimates were converted to Z-scores derived from the regression
953 coefficients (betas) divided by their standard errors, with direction of effect aligned to
954 reflect the additive effect of HF-risk-increasing allele. Loci and GWAS traits were
955 ordered using hierarchical agglomerative clustering with average linkage method,
956 implemented with the *hclust* function in R 4.2.0. Distances between loci / traits for
957 clustering were calculated with the Euclidean method using vectors of absolute Z-
958 scores (reflecting allele-agnostic effects across tested loci / traits).

959

960 **Cross-trait colocalisation**

961 To test whether locus-specific genetic associations with HF and a given trait derived
962 from common causal variants, we performed pairwise cross-trait colocalisation
963 analysis implemented in R *coloc* package¹⁵, allowing multiple causal variants per locus
964 by integrating Sum of Single Effects (SuSiE) regression framework⁷⁶. This approach
965 first runs SuSiE to detect credible set(s) L_1 and L_2 corresponding to trait 1 and trait 2
966 respectively; followed by colocalisation to estimate posterior probabilities of common
967 causal variants (hypothesis 4, H_4) for each pairwise combination of elements of $L_1 \times$
968 L_2 ¹⁵. To run *coloc*, we used the default marginal prior probabilities for association with
969 trait 1 (p_1) and trait 2 (p_2) of 10^{-4} , and a prior probability of joint causal association (p_{12})

970 of 10^{-5} . A posterior probability of H_4 ($PP_{coloc H_4}$) >0.8 in at least one pair of credible sets
971 was considered as evidence of shared causal variants. The colocalisation analysis
972 was performed for each identified HF locus using an overlapping set of variants
973 available in both GWAS of HF and trait under analysis situated within the locus.
974 Genetic association estimates for HF were extracted from GWAS of the overall HF
975 phenotype for loci with $P_{HF} < 5 \times 10^{-8}$ (locus 1-56); or otherwise from GWAS of non-
976 ischaemic HF phenotypes for subtype-specific loci: ni-HF for locus 57-61, ni-HFrEF
977 for locus 62-64, and ni-HFpEF for locus 65-66.

978

979 **Genetic correlation**

980 To assess the extent to which genetic associations are shared amongst HF subtypes,
981 we performed genetic correlation analysis across pairs of 4 HF subtypes under
982 analysis, and genetic correlation between pairwise combinations of each HF subtype
983 and 24 HF-related GWAS traits. The genetic correlation analysis was performed using
984 bivariate linkage disequilibrium score (LDSC) regression¹⁰¹ with input GWAS
985 summary statistics taken from the present study (for HF phenotypes) and publicly
986 available data (for other traits). Genetic correlation of HF and other binary traits was
987 estimated on a liability scale, with sample prevalence estimated as the number of
988 cases divided by total number of samples in the GWAS and population prevalence
989 taken from literatures if available, or assumed to equate the sample prevalence
990 otherwise (**Supplementary Table 23**).

991

992 **Mendelian randomisation**

993 We estimated the causal effects of each of the 24 HF-related traits (**Supplementary**
994 **Table 23**) on each of the 4 HF subtypes analysed in the present study using two-
995 sample Mendelian randomization (MR) as implemented in the
996 *MendelianRandomization* package¹⁰². MR instruments for the exposure traits
997 (phenotypes other than HF) were selected from genetic variants available in both
998 GWAS of exposure and outcome (HF phenotypes) traits using LD-based clumping
999 algorithm with P value threshold of 5×10^{-8} and LD r^2 threshold of 0.05 implemented
1000 in PLINK¹⁰⁰. For each exposure trait, we estimated the causal association with each
1001 HF phenotype using inverse-variance weighted (IVW) MR estimator; and performed
1002 sensitivity analyses with MR-Egger and weighted median estimators (WME)^{103,104}.
1003 Traits that survived the multiple testing adjustment at FDR <1% in IVW analysis and
1004 showed consistent direction of effect in sensitivity analyses were considered causal.

1005

1006 **Multiple testing adjustment**

1007 Where mentioned in the text, we performed multiple testing adjustments by controlling
1008 false discovery rate (FDR) using the Benjamini-Hochberg procedure¹⁰⁵ as
1009 implemented in the *p.adjust(method = "BH")* function in *R*. For each analysis, adjusted
1010 P -values less than a tolerable type-I error rate (alpha) of 0.01, corresponding to false
1011 discovery rate of 1%, were considered to survive the multiple testing correction.

Figures




Figure 1.a. Phenotyping schema **b.** Manhattan plots of 4 HF subtypes. **c.** Summary of conditionally independent lead variants across HF phenotypes. Lead variants are denoted using chromosome and base pair position according to GRCh37 assembly. RR = risk ratio, EA = effect allele, aligned to risk-increasing allele in HF phenotype with lowest P value for association; OA = other (non-effect) allele; EAF = effect allele frequency, P_{het} = P value for effect estimate heterogeneity across studies. EAF and P_{het} estimates were taken from the first HF phenotype with genome-wide significant lead variant.




Figure 3. a. Enriched terms (Penrichment < 0.05) from Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Human Phenotype Ontology (HP), Reactome (REAC), and Wiki Pathways (WP). Up to top 20 enriched terms in each HF phenotype gene set are labelled. **b.** Heritability enrichment of 206 tissues and cell types, classified into 12 system / organ categories, across 4 HF phenotypes. Top 5 tissues / cell types per phenotype are labelled.




Figure 4. Aetiologic clusters identified through locus-phenotype pleiotropy network analysis of the phenome-wide association estimates. Nodes represent loci (solid background) and phenotype (translucent background), with size representing centrality measure. Edges represent locus-phenotype association, with thickness representing strength of association measured by absolute Z score.




Figure 5. a. Colocalisations between HF and 22 GWAS phenotypes (out of 24 tested) across 42 (out of 66) loci with posterior probability of shared causal variants ($PP_{coloc\ H4}$) > 0.8. Each band connects a pair of locus - phenotype nodes, and represents sharing of causal variants between the phenotype and HF at the locus. Annotated number represents total number of colocalisations by locus and phenotype, which is displayed in panel **b. & c.**




Figure 6. Bivariate genetic correlation (r_g) and Mendelian randomisation (MR) estimates across 24 traits and 4 HF phenotypes. Asterisks (*) indicate binary traits. MR effects estimates are reported as odds ratio (OR_{MR}) per doubling prevalence for binary traits; or per standard deviation increase for quantitative traits. Estimates which were robust to multiple testing adjustment and sensitivity analyses were indicated by light blue shade (for $r_g < 0$ and $OR_{MR} < 1$) or light red shade (for $r_g > 0$ and $OR_{MR} > 1$). The heat maps represent P -values for different MR models, colour-coded with direction of MR estimates and strength of associations.

Data availability

GWAS summary statistics from the meta-analysis will be made available on the Cardiovascular Disease Knowledge Portal (<https://cvd.hugeamp.org/>) and GWAS Catalog (<https://www.ebi.ac.uk/gwas/summary-statistics>) upon publication.

Code availability

A sample code to define heart failure phenotypes in UK Biobank is available on: <https://github.com/ihi-comp-med/ukb-hf-phenotyping>. Other codes to perform key analyses presented in this work will be made available on <https://github.com/ihi-comp-med/hermes2-gwas>

Acknowledgements

A.Henry was supported by the BHF Cardiovascular Biomedicine PhD studentship (FS/18/65/34186). R.T.L. and A.Henry are partly supported by a Pfizer Innovative Targets Exploration Network Grant. The project was additionally supported by BigData@Heart Consortium funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074, the UCL British Heart Foundation Accelerator (AA/18/6/34223), National Institute for Health Research University College London Hospitals Biomedical Research Centre (NIHR203328), and Health Data Research UK (MR/S003754/1). Analyses using the UK Biobank resource presented in this work were conducted under Application Numbers 9922, 15422, 12113, and 47602. The authors thank all research participants included in the presented work. The views expressed in this work are those of the authors and not necessarily those of the funders. Additional study-level acknowledgements are provided in **Supplementary Table 18**.

Author contributions

Conceptualisation: R.S.V., J.G.S., H.Holm, Sonia Shah, P.T.E., A.D.H., Q.W., R.T.L.

Methodology: A.Henry, M.D.C., D.S., Sonia Shah

Project administration: A.Henry, H.I., D.M., R.T.L.

Formal analysis: A.Henry, X.M.

Software: A.Henry, C.F., D.S., S.C., A.F.S.

Data Curation: A.Henry, H.I.

Writing - Original Draft: A.Henry, R.T.L.

Visualisation: A.Henry

Resources: C.F., M.D.C., S.D., J.Gratton, S.C., J.G.S., H.Holm, P.T.E., A.D.H.

Investigation: M.D.C., I.B., C.R., D.M.

Supervision: F.W.A., T.P.C., M.P.D., M.E.D., C.C.L., N.J.S., R.S.V., J.G.S., H.Holm, Sonia Shah, P.T.E., A.D.H., Q.W., R.T.L.

Funding acquisition: R.T.L.

F.W.A., T.P.C., M.P.D., M.E.D., C.C.L., N.J.S., Svati Shah, R.S.V., J.G.S., H.Holm, P.T.E., A.D.H., Q.W., R.T.L. are members of the HERMES Executive Committee who provided additional supervision of the work.

Other co-authors not listed above contributed to data generation, funding acquisition, formal analysis, and supervision at individual study level.

Lists of contributors from Genes & Health Research Team, DBDS Genomic Consortium, and HERMES Consortium are provided in **Supplementary Note**.

All authors have reviewed and approved the final version of the manuscript.

Competing interests

A.Henry and R.T.L. received funding from Pfizer. J.S.W. have acted as a consultant for MyoKardia, Pfizer, Foresite Labs, and Health Lumen, and received institutional support from Bristol-Myers Squibb and Pfizer. S.d.D. was supported through grants from AstraZeneca, Roche Molecular Science/DalCor. J.R.K. declares stock ownership in AbbVie, Abbott, Bristol Myers Squibb, Johnson & Johnson, Medtronic, Merck, Pfizer. N.A.M. received speaking honoraria from Amgen and is involved in clinical trials with Ionis, Amgen, Pfizer, and Novartis. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. C.T.R. received honoraria for scientific advisory boards and consulting from Anthos, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, and received institutional research grants from Anthos, AstraZeneca, Daiichi Sankyo, Janssen and Novartis. M.S.S. received significant research grant support from Abbott Laboratories, Amgen, AstraZeneca, Bayer, Critical Diagnostics, Daiichi-Sankyo, Eisai, Genzyme, Gilead, GlaxoSmithKline, Intarcia, Janssen Research and Development, The Medicines Company, MedImmune, Merck, Novartis, Poxel, Pfizer, Quark Pharmaceuticals, Roche Diagnostics, and Takeda; and has received consulting fees from Alnylam, AstraZeneca, Bristol-Myers Squibb, CVS, Amgen. A.A.V. received consultancy fees and/or research support from AnaCardia, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Corteria, Cytokinetics, EliLilly, Moderna, Novartis, NovoNordisk, Roche Diagnostics. M-P.D. declares holding equity in Dalcor Pharmaceuticals, unrelated to this work.

Members of the TIMI Study Group (ENGAGE, FOURIER, PEGASUS, SAVOR, SOLID) have received institutional research grant support through Brigham and Women's Hospital from: Abbott, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Roche, Siemens Healthcare Diagnostics, Inc., Softcell Medical Limited, The Medicines Company, Zora Biosciences, Caremark, Dyrnamix, Esperon, IFM Pharmaceuticals, MyoKardia.

The authors who are affiliated with deCODE genetics/Amgen Inc. and the authors affiliated with Pfizer Inc. declare competing financial interests as employees.

The remaining authors declare no competing interests.

References

1. Shah, S. *et al.* Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat. Commun.* **11**, 163 (2020).
2. Levin, M. G. *et al.* Genome-wide association and multi-trait analyses characterize the common genetic architecture of heart failure. *Nat. Commun.* **13**, 6914 (2022).
3. Joseph, J. *et al.* Genetic architecture of heart failure with preserved versus reduced ejection fraction. *Nat. Commun.* **13**, 1–14 (2022).
4. Arvanitis, M. *et al.* Genome-wide association and multi-omic analyses reveal ACTN2 as a gene linked to heart failure. *Nat. Commun.* **11**, 1122 (2020).
5. Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. *Cell Genomics* **2**, (2022).
6. Garnier, S. *et al.* Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. *Eur. Heart J.* **42**, 2000–2011 (2021).
7. Weissbrod, O. *et al.* Functionally informed fine-mapping and polygenic localization of complex trait heritability. *Nat. Genet.* **52**, 1355–1363 (2020).
8. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886–D894 (2019).
9. Ortiz-Genga, M. F. *et al.* Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. *J. Am. Coll. Cardiol.* **68**, 2440–2451 (2016).
10. Domínguez, F. *et al.* Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations. *J. Am. Coll. Cardiol.* **72**, 2471–2481 (2018).
11. Wu, T. *et al.* HSPB7 is indispensable for heart development by modulating actin filament assembly. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 11956–11961 (2017).
12. Ghousaini, M. *et al.* Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* **49**, D1311–D1320 (2021).
13. Weeks, E. M. *et al.* Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. *bioRxiv* (2020) doi:10.1101/2020.09.08.20190561.
14. Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves association detection. *PLoS Genet.* **15**, e1007889 (2019).
15. Wallace, C. A more accurate method for colocalisation analysis allowing for multiple causal variants. *PLoS Genet.* **17**, e1009440 (2021).
16. Sobczyk, M. K., Gaunt, T. R. & Paternoster, L. MendelVar: gene prioritization at GWAS loci using phenotypic enrichment of Mendelian disease genes. *Bioinformatics* **37**, 1–8 (2021).
17. Sanan, D. A. *et al.* Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). *Proc. Natl. Acad. Sci. U. S. A.* **95**, 4544–4549 (1998).
18. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C. & Witztum, J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. *N. Engl. J. Med.* **320**, 915–924 (1989).
19. Berge, K. E. *et al.* Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. *Science* **290**, 1771–1775 (2000).
20. Lee, M. H. *et al.* Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. *Nat. Genet.* **27**, 79–83 (2001).
21. Kronenberg, F. *et al.* Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur. Heart J.* **43**, 3925–3946 (2022).
22. Congrains, A. *et al.* Genetic variants at the 9p21 locus contribute to atherosclerosis through

- modulation of ANRIL and CDKN2A/B. *Atherosclerosis* **220**, 449–455 (2012).
23. Chiu, C. *et al.* Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. *J. Am. Coll. Cardiol.* **55**, 1127–1135 (2010).
 24. Ling, H. *et al.* Requirement for Ca²⁺/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. *J. Clin. Invest.* **119**, 1230–1240 (2009).
 25. Meurs, K. M. *et al.* Association of dilated cardiomyopathy with the striatin mutation genotype in boxer dogs. *J. Vet. Intern. Med.* **27**, 1437–1440 (2013).
 26. Wang, J. *et al.* *Pitx2* prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 9753–9758 (2010).
 27. Sotoodehnia, N. *et al.* Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. *Nat. Genet.* **42**, 1068–1076 (2010).
 28. Pfeufer, A. *et al.* Common variants at ten loci modulate the QT interval duration in the QTSCD Study. *Nat. Genet.* **41**, 407–414 (2009).
 29. Górska, A. A. *et al.* Muscle-specific *Cand2* is translationally upregulated by mTORC1 and promotes adverse cardiac remodeling. *EMBO Rep.* **22**, e52170 (2021).
 30. Benson, D. W. *et al.* Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. *J. Clin. Invest.* **104**, 1567–1573 (1999).
 31. Pashmforoush, M. *et al.* *Nkx2-5* pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. *Cell* **117**, 373–386 (2004).
 32. Sveinbjornsson, G. *et al.* Variants in *NKX2-5* and *FLNC* Cause Dilated Cardiomyopathy and Sudden Cardiac Death. *Circ Genom Precis Med* **11**, e002151 (2018).
 33. Copeland-Halperin, R. S., Liu, J. E. & Yu, A. F. Cardiotoxicity of HER2-targeted therapies. *Curr. Opin. Cardiol.* **34**, 451–458 (2019).
 34. Christensen, G., Herum, K. M. & Lunde, I. G. Sweet, yet underappreciated: Proteoglycans and extracellular matrix remodeling in heart disease. *Matrix Biol.* **75-76**, 286–299 (2019).
 35. Johnston, J. A., Ward, C. L. & Kopito, R. R. Aggresomes: a cellular response to misfolded proteins. *J. Cell Biol.* **143**, 1883–1898 (1998).
 36. Martin, T. G. *et al.* Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover. *Nat. Commun.* **12**, 2942 (2021).
 37. Zhang, L. *et al.* Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure. *Nature Cardiovascular Research* **1**, 1195–1214 (2022).
 38. Oakley, R. H. & Cidlowski, J. A. Glucocorticoid signaling in the heart: A cardiomyocyte perspective. *J. Steroid Biochem. Mol. Biol.* **153**, 27–34 (2015).
 39. Chaffin, M. *et al.* Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy. *Nature* (2022) doi:10.1038/s41586-022-04817-8.
 40. Oakley, R. H. *et al.* Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice. *Sci. Signal.* **12**, (2019).
 41. Rossignol, P. *et al.* Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHEsus (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. *J. Am. Coll. Cardiol.* **58**, 1958–1966 (2011).
 42. Tan, W. L. W. *et al.* Epigenomes of Human Hearts Reveal New Genetic Variants Relevant for Cardiac Disease and Phenotype. *Circ. Res.* **127**, 761–777 (2020).
 43. Kuan, V. *et al.* A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. *Lancet Digit Health* **1**, e63–e77 (2019).
 44. Tadros, R. *et al.* Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nat. Genet.* **53**, 128–134 (2021).
 45. Jia, M. *et al.* Deletion of *BACH1* Attenuates Atherosclerosis by Reducing Endothelial

- Inflammation. *Circ. Res.* **130**, 1038–1055 (2022).
46. Xin, M. *et al.* Hippo pathway effector Yap promotes cardiac regeneration. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 13839–13844 (2013).
 47. Blake, J. A. *et al.* Mouse Genome Database (MGD): Knowledgebase for mouse-human comparative biology. *Nucleic Acids Res.* **49**, D981–D987 (2021).
 48. Ochoa, D. *et al.* The next-generation Open Targets Platform: reimaged, redesigned, rebuilt. *Nucleic Acids Res.* **51**, D1353–D1359 (2023).
 49. Ware, J. S. *et al.* Genetic Etiology for Alcohol-Induced Cardiac Toxicity. *J. Am. Coll. Cardiol.* **71**, 2293–2302 (2018).
 50. Banerjee, A. *et al.* A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential. *Eur. J. Heart Fail.* **24**, 466–480 (2022).
 51. Wehner, G. J. *et al.* Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? *Eur. Heart J.* **41**, 1249–1257 (2020).
 52. Harris, P. Evolution and the cardiac patient. *Cardiovasc. Res.* **17**, 437–445 (1983).
 53. Bianucci, R. *et al.* Forensic Analysis Reveals Acute Decompensation of Chronic Heart Failure in a 3500-Year-Old Egyptian Dignitary. *J. Forensic Sci.* **61**, 1378–1381 (2016).
 54. Vaduganathan, M. *et al.* SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. *Lancet* **400**, 757–767 (2022).
 55. Lumbers, R. T. *et al.* Body mass index and heart failure risk: a cohort study in 1.5 million individuals and Mendelian randomisation analysis. *medRxiv* 2020.09.23.20200360 (2020).
 56. Löfman, I., Szummer, K., Dahlström, U., Jernberg, T. & Lund, L. H. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. *Eur. J. Heart Fail.* **19**, 1606–1614 (2017).
 57. Di Micco, R., Krizhanovsky, V., Baker, D. & d’Adda di Fagagna, F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. *Nat. Rev. Mol. Cell Biol.* **22**, 75–95 (2021).
 58. Bracun, V. *et al.* Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. *ESC Heart Fail* (2022) doi:10.1002/ehf2.14120.
 59. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* **48**, 1279–1283 (2016).
 60. 1000 Genomes Project Consortium *et al.* A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061–1073 (2010).
 61. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290–299 (2021).
 62. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–518 (2023).
 63. Ishigaki, K. *et al.* Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. *Nat. Genet.* **52**, 669–679 (2020).
 64. Mölder, F. *et al.* Sustainable data analysis with Snakemake. *F1000Res.* **10**, 33 (2021).
 65. Winkler, T. W. *et al.* Quality control and conduct of genome-wide association meta-analyses. *Nat. Protoc.* **9**, 1192–1212 (2014).
 66. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
 67. Mägi, R. *et al.* Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. *Hum. Mol. Genet.* **26**, 3639–3650 (2017).
 68. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–75, S1–3 (2012).
 69. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

70. Dabney, A., Storey, J. D. & Warnes, G. R. qvalue: Q-value estimation for false discovery rate control. *R package version 1*, (2010).
71. Speed, D. & Balding, D. J. SumHer better estimates the SNP heritability of complex traits from summary statistics. *Nat. Genet.* **51**, 277–284 (2019).
72. Speed, D., Holmes, J. & Balding, D. J. Evaluating and improving heritability models using summary statistics. *Nat. Genet.* **52**, 458–462 (2020).
73. Ojavee, S. E., Kutalik, Z. & Robinson, M. R. Liability-scale heritability estimation for biobank studies of low-prevalence disease. *Am. J. Hum. Genet.* **109**, 2009–2017 (2022).
74. Grotzinger, A. D., Fuente, J. de la, Privé, F., Nivard, M. G. & Tucker-Drob, E. M. Pervasive Downward Bias in Estimates of Liability-Scale Heritability in Genome-wide Association Study Meta-analysis: A Simple Solution. *Biol. Psychiatry* (2022) doi:10.1016/j.biopsych.2022.05.029.
75. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics* **36**, 5424–5431 (2020).
76. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Series B Stat. Methodol.* **82**, 1273–1300 (2020).
77. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164 (2010).
78. Mountjoy, E. *et al.* An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. *Nat. Genet.* **53**, 1527–1533 (2021).
79. The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318–1330 (2020).
80. Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *J. Mach. Learn. Res.* **12**, 2825–2830 (2011).
81. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).
82. Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun.* **6**, 5890 (2015).
83. Fehrmann, R. S. N. *et al.* Gene expression analysis identifies global gene dosage sensitivity in cancer. *Nat. Genet.* **47**, 115–125 (2015).
84. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
85. Fleming, S. J. *et al.* Unsupervised removal of systematic background noise from droplet-based single-cell experiments using CellBender. *bioRxiv* 791699 (2022) doi:10.1101/791699.
86. Zheng, G. X. Y. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* **8**, 14049 (2017).
87. Tucker, N. R. *et al.* Transcriptional and Cellular Diversity of the Human Heart. *Circulation* **142**, 466–482 (2020).
88. Ma, Y. *et al.* Cardiomyocyte d-dopachrome tautomerase protects against heart failure. *JCI Insight* **4**, (2019).
89. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47–e47 (2015).
90. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29 (2014).
91. Raudvere, U. *et al.* g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Res.* **47**, W191–W198 (2019).
92. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res.* **44**, D457–62 (2016).
93. Gillespie, M. *et al.* The reactome pathway knowledgebase 2022. *Nucleic Acids Res.* **50**, D687–D692 (2022).

94. Slenter, D. N. *et al.* WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. *Nucleic Acids Res.* **46**, D661–D667 (2018).
95. Ashburner, M. *et al.* Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat. Genet.* **25**, 25–29 (2000).
96. Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. *Nucleic Acids Res.* **49**, D325–D334 (2021).
97. Davidson, R. & Harel, D. Drawing graphs nicely using simulated annealing. *ACM Trans. Graph.* **15**, 301–331 (1996).
98. Pons, P. & Latapy, M. Computing Communities in Large Networks Using Random Walks. in *Computer and Information Sciences - ISICIS 2005* 284–293 (Springer Berlin Heidelberg, 2005).
99. Newman, M. E. J. Modularity and community structure in networks. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 8577–8582 (2006).
100. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
101. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
102. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int. J. Epidemiol.* **46**, 1734–1739 (2017).
103. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* **44**, 512–525 (2015).
104. Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat. Med.* **35**, 1880–1906 (2016).
105. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Series B Stat. Methodol.* **57**, 289–300 (1995).